CSBTF Stock Chart & Stats
$25.90
$0.00(0.00%)
At close: 4:00 PM EDT
$25.90
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$18.40 - $42.81
Previous CloseN/A
Volume10.00
Average Volume (3M)117.00
Market Cap
$852.92M
Enterprise Value$776.03
Total Cash (Recent Filing)$7.85M
Total Debt (Recent Filing)$11.01M
Price to Earnings (P/E)99.3
Beta0.83
Next Earnings
Mar 17, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.18
Shares Outstanding39,673,230
10 Day Avg. Volume0
30 Day Avg. Volume117
Financial Highlights & Ratios
PEG Ratio-3.21
Price to Book (P/B)15.78
Price to Sales (P/S)8.71
P/FCF Ratio-439.50
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$38.97Price Target Upside50.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.49
Revenue Forecast (FY)$255.70M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth And High Gross MarginsRevenue scale-up and very high gross margins indicate strong product economics and expanding commercial traction. These characteristics can support reinvestment, operating leverage, and improving earnings power as Kuros broadens adoption across spine and orthopedic procedures.
Conservatively Financed Balance SheetVery low leverage reduces interest burden and preserves financial flexibility while Kuros invests in manufacturing capacity and commercial growth. A conservatively financed balance sheet should improve resilience if implementation takes longer or profitability fluctuates during expansion.
Growing Market Reach And ShareBroader distributor coverage and substantial market-share gains point to increasing commercial penetration rather than reliance on a single growth event. Continued surgeon utilization and account expansion could strengthen Kuros's position and support durable product demand.
Bears Say
Weak Cash ConversionNegative operating and free cash flow despite reported profitability shows that earnings are not yet converting consistently into cash. If this persists, Kuros may have less internally generated funding for expansion and greater sensitivity to working-capital swings or investment needs.
Profitability Remains Thin And Recently EstablishedThe move into profitability is encouraging, but the modest net margin leaves limited protection against slower growth, pricing pressure, or higher operating costs. Because positive earnings are recent, Kuros still needs sustained execution to establish a durable profitability base.
Manufacturing Ramp And Working Capital PressureExpansion is creating near-term financial pressure through elevated receivables and the transition to U.S. production. Margin dilution and cash tied up in working capital could constrain funding flexibility until the manufacturing ramp stabilizes and receivables normalize.
Kuros Biosciences News
CSBTF FAQ
What was Kuros Biosciences Ltd.’s price range in the past 12 months?
Kuros Biosciences Ltd. lowest stock price was $18.40 and its highest was $42.81 in the past 12 months.
What is Kuros Biosciences Ltd.’s market cap?
Kuros Biosciences Ltd.’s market cap is $852.92M.
When is Kuros Biosciences Ltd.’s upcoming earnings report date?
Kuros Biosciences Ltd.’s upcoming earnings report date is Mar 17, 2027 which is in 168 days.
How were Kuros Biosciences Ltd.’s earnings last quarter?
Kuros Biosciences Ltd. released its earnings results on Aug 13, 2026. The company reported $0.074 earnings per share for the quarter, beating the consensus estimate of $0.072 by $0.002.
Is Kuros Biosciences Ltd. overvalued?
According to Wall Street analysts Kuros Biosciences Ltd.’s price is currently Undervalued.
Does Kuros Biosciences Ltd. pay dividends?
Kuros Biosciences Ltd. does not currently pay dividends.
What is Kuros Biosciences Ltd.’s EPS estimate?
Kuros Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kuros Biosciences Ltd. have?
Kuros Biosciences Ltd. has 39,673,230 shares outstanding.
What happened to Kuros Biosciences Ltd.’s price movement after its last earnings report?
Kuros Biosciences Ltd. reported an EPS of $0.074 in its last earnings report, beating expectations of $0.072. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Kuros Biosciences Ltd.?
Currently, no hedge funds are holding shares in CSBTF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kuros Biosciences Ltd.
Kuros Biosciences AG functions as a biopharmaceutical enterprise, dedicated to both the development and market introduction of advanced therapeutic solutions for tissue regeneration and bone repair. Its operations span across the United States, the European Union, and other global regions. The company's business activities are structured into three main segments: Medical Devices, Pharmaceuticals, and a Legacy Portfolio. Its orthobiologics product line includes MagnetOs Granules and MagnetOs Putty, available in EU and US markets for various orthopedic, spinal, and dental applications. Within its fibrin/PTH orthobiologics pipeline, KUR-111 has successfully completed a Phase 2b clinical trial for treating tibial plateau fractures. Similarly, KUR-113 has concluded its Phase 2b clinical trial for tibial shaft fractures and is currently undergoing a Phase II trial for spinal interbody fusion procedures. Additionally, Kuros offers sealant products such as Neuroseal, a synthetic tissue sealant marketed in the EU and US, engineered to prevent cerebrospinal fluid leakage after cranial or spinal surgeries. The company also engages in a collaborative endeavor with Checkmate Pharmaceuticals LLC for the advancement of CYT003, intended for oncology treatments. Kuros Biosciences AG is headquartered in Schlieren, Switzerland.
CSBTF Company Deck
CSBTF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong set of operational and financial achievements (robust +45% H1 revenue growth, first sustained half‑year profitability with CHF 12.5M adjusted EBITDA and CHF 4.4M net profit, improving gross margins, strong clinical evidence and a clear midterm revenue/margin target). These positives are tempered by planned near‑term investments and transformation costs, expected dilution from the U.S. manufacturing ramp, lumpiness in international revenue, and working capital accumulation that creates short-term liquidity sensitivity. On balance, the transformational investments are framed as deliberate and the company maintained conservative near-term guidance while presenting a credible path to >20% adjusted EBITDA by 2028, so the overall tone is confident with manageable near-term risks.View all CSBTF earnings summariesCSBTF Stock 12 Month Forecast
Average Price Target
$38.97
▲(50.46% Upside)
Technical Analysis
Molecular Partners AG
―
Lonza Group Ltd
―
Basilea Pharmaceutica
―
Idorsia Ltd
―
Bachem Holding AG
―
Ownership Overview
―
Insiders
0.73% Mutual Funds
― Other Institutional Investors
97.28% Public Companies and
Individual Investors